0001516551-23-000096.txt : 20231106
0001516551-23-000096.hdr.sgml : 20231106
20231106202959
ACCESSION NUMBER: 0001516551-23-000096
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231106
FILED AS OF DATE: 20231106
DATE AS OF CHANGE: 20231106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ARSENAULT KAITLYN
CENTRAL INDEX KEY: 0001877242
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-55136
FILM NUMBER: 231381272
MAIL ADDRESS:
STREET 1: 11250 EL CAMINO REAL, SUITE 100
STREET 2: C/O SKYE BIOSCIENCE, INC.
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER NAME:
FORMER CONFORMED NAME: Arsenault Kaitlyn Melanie
DATE OF NAME CHANGE: 20210806
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Skye Bioscience, Inc.
CENTRAL INDEX KEY: 0001516551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 450692882
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11250 EL CAMINO REAL, SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 410-0266
MAIL ADDRESS:
STREET 1: 11250 EL CAMINO REAL, SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Emerald Bioscience, Inc.
DATE OF NAME CHANGE: 20190325
FORMER COMPANY:
FORMER CONFORMED NAME: Nemus Bioscience, Inc.
DATE OF NAME CHANGE: 20141030
FORMER COMPANY:
FORMER CONFORMED NAME: LOAD GUARD LOGISTICS, INC.
DATE OF NAME CHANGE: 20121107
4
1
wk-form4_1699320590.xml
FORM 4
X0508
4
2023-11-06
0
0001516551
Skye Bioscience, Inc.
SKYE
0001877242
ARSENAULT KAITLYN
11250 EL CAMINO REAL, SUITE 100
C/O SKYE BIOSCIENCE, INC.
SAN DIEGO
CA
92130
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-11-06
4
A
0
128209
0
A
185738
D
Stock Option (Right to Buy)
3.50
2023-11-06
4
A
0
32053
0
A
2033-08-25
Common Stock
32053
45436
D
Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $125M, an additional 25% vests upon achieving a market cap of $250M, an additional 25% vests upon achieving a market cap of $400M, an additional 25% vest at an exit of $500M or greater; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Notwithstanding anything to the foregoing, all of the RSUS shall vest if an exit greater than $500M is achieved at an earlier date.
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the four year period beginning August 24, 2023. Upon a change in control of the Issuer, 100% of the options will become fully vested.
/s/ Kaitlyn Arsenault
2023-11-06